Futermestotug

伏泰苏塔单抗

Report date: 2026/03/31 15:44:44

Base Information

Drug NameFutermestotug
Drug Alias NameYH-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryArmeniaUnited StatesTaiwan +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesEucure Pharmaceutical Technology (Beijing) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTracon Pharmaceuticals IncEucure Pharmaceutical Technology (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursMelanomaSarcoma
Inactive IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A